IQVIA (NYSE:IQV) Releases FY 2026 Earnings Guidance

IQVIA (NYSE:IQV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 12.650-12.950 for the period, compared to the consensus estimate of 12.460. The company issued revenue guidance of $17.2 billion-$17.4 billion, compared to the consensus revenue estimate of $17.2 billion.

Analysts Set New Price Targets

A number of brokerages have issued reports on IQV. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Tuesday, April 21st. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, April 19th. Morgan Stanley set a $240.00 price target on IQVIA in a report on Wednesday, February 11th. UBS Group lowered their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $226.63.

IQVIA Trading Up 1.1%

Shares of NYSE IQV traded up $1.93 during mid-day trading on Wednesday, reaching $178.35. 595,795 shares of the company’s stock were exchanged, compared to its average volume of 1,947,695. The firm has a market capitalization of $30.27 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 1.60 and a beta of 1.18. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a 52-week low of $134.65 and a 52-week high of $247.04. The company’s 50-day moving average is $169.57 and its 200-day moving average is $201.34.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the business posted $2.70 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts expect that IQVIA will post 11.5 EPS for the current fiscal year.

IQVIA News Summary

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q1 beat on the headline numbers: EPS $2.90 vs. consensus $2.83 and revenue $4.15B vs. $4.10B — the upside drove the immediate bullish reaction. IQVIA Reports First-Quarter 2026 Results
• Positive Sentiment: Company lifted FY2026 EPS guidance to $12.65–$12.95, above Wall Street’s prior consensus, signaling stronger profitability expectations for the year. IQVIA lifts EPS outlook after record Q1 results
• Positive Sentiment: Commercial Solutions and AI-backed offerings were highlighted as growth drivers and strong bookings supported revenue expansion — a structural growth story investors favor. IQV Q1 Earnings Beat on Commercial Solutions Strength
• Neutral Sentiment: Management kept revenue and EBITDA guidance relatively steady while raising EPS, a mixed signal that suggests margin or mix improvements rather than faster topline acceleration. IQVIA 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Call transcript and slides provide color on bookings, client demand and product mix — useful for gauging sustainability but not an immediate catalyst. IQVIA Q1 2026 Earnings Call Transcript
• Negative Sentiment: Balance-sheet and valuation considerations: leverage is relatively high (debt/equity ~2.09) and liquidity ratios are low; the stock remains below its 200‑day moving average, which could limit upside for risk‑averse investors.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently bought and sold shares of the company. Gilpin Wealth Management LLC purchased a new position in IQVIA during the 4th quarter valued at about $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the 4th quarter valued at about $28,000. Measured Wealth Private Client Group LLC purchased a new position in IQVIA during the 3rd quarter valued at about $30,000. DV Equities LLC purchased a new position in IQVIA during the 4th quarter valued at about $53,000. Finally, Johnson Financial Group Inc. purchased a new position in IQVIA during the 3rd quarter valued at about $52,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.